Logo image of MAZE

MAZE THERAPEUTICS INC (MAZE) Stock Fundamental Analysis

USA - NASDAQ:MAZE - US5787841007 - Common Stock

23.295 USD
-1.5 (-6.07%)
Last: 9/12/2025, 8:00:01 PM
23.78 USD
+0.48 (+2.08%)
After Hours: 9/12/2025, 8:00:01 PM
Fundamental Rating

4

MAZE gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. MAZE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. MAZE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

MAZE had positive earnings in the past year.
In the past year MAZE has reported a negative cash flow from operations.
MAZE Yearly Net Income VS EBIT VS OCF VS FCFMAZE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

MAZE has a better Return On Assets (1.12%) than 81.54% of its industry peers.
MAZE's Return On Equity of 1.30% is amongst the best of the industry. MAZE outperforms 81.03% of its industry peers.
The Return On Invested Capital of MAZE (16.04%) is better than 93.85% of its industry peers.
Industry RankSector Rank
ROA 1.12%
ROE 1.3%
ROIC 16.04%
ROA(3y)-71.89%
ROA(5y)N/A
ROE(3y)-370.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MAZE Yearly ROA, ROE, ROICMAZE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

With an excellent Profit Margin value of 2.03%, MAZE belongs to the best of the industry, outperforming 80.51% of the companies in the same industry.
MAZE has a better Operating Margin (34.38%) than 95.90% of its industry peers.
Industry RankSector Rank
OM 34.38%
PM (TTM) 2.03%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MAZE Yearly Profit, Operating, Gross MarginsMAZE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 10 20 30

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MAZE is still creating some value.
Compared to 1 year ago, MAZE has about the same amount of shares outstanding.
MAZE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MAZE Yearly Shares OutstandingMAZE Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
MAZE Yearly Total Debt VS Total AssetsMAZE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

MAZE has an Altman-Z score of 16.02. This indicates that MAZE is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of MAZE (16.02) is better than 90.26% of its industry peers.
There is no outstanding debt for MAZE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.02
ROIC/WACC1.62
WACC9.91%
MAZE Yearly LT Debt VS Equity VS FCFMAZE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

MAZE has a Current Ratio of 13.63. This indicates that MAZE is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 13.63, MAZE belongs to the best of the industry, outperforming 87.18% of the companies in the same industry.
A Quick Ratio of 13.63 indicates that MAZE has no problem at all paying its short term obligations.
MAZE has a better Quick ratio (13.63) than 87.18% of its industry peers.
Industry RankSector Rank
Current Ratio 13.63
Quick Ratio 13.63
MAZE Yearly Current Assets VS Current LiabilitesMAZE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 103.39% over the past year.
EPS 1Y (TTM)103.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-413.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

MAZE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.23% yearly.
The Revenue is expected to decrease by -72.91% on average over the next years. This is quite bad
EPS Next Y84.51%
EPS Next 2Y36.71%
EPS Next 3Y23.23%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-72.91%
Revenue Next 5YN/A

3.3 Evolution

MAZE Yearly Revenue VS EstimatesMAZE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2027 50M 100M 150M
MAZE Yearly EPS VS EstimatesMAZE Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -5 -10 -15 -20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

MAZE is valuated quite expensively with a Price/Earnings ratio of 291.19.
Based on the Price/Earnings ratio, MAZE is valued a bit cheaper than 76.41% of the companies in the same industry.
When comparing the Price/Earnings ratio of MAZE to the average of the S&P500 Index (27.30), we can say MAZE is valued expensively.
The Forward Price/Earnings Ratio is negative for MAZE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 291.19
Fwd PE N/A
MAZE Price Earnings VS Forward Price EarningsMAZE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200 250

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, MAZE is valued cheaper than 85.13% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.62
MAZE Per share dataMAZE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as MAZE's earnings are expected to grow with 23.23% in the coming years.
PEG (NY)3.45
PEG (5Y)N/A
EPS Next 2Y36.71%
EPS Next 3Y23.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MAZE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAZE THERAPEUTICS INC

NASDAQ:MAZE (9/12/2025, 8:00:01 PM)

After market: 23.78 +0.48 (+2.08%)

23.295

-1.5 (-6.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)N/A N/A
Inst Owners75.38%
Inst Owner Change-7.34%
Ins Owners5.91%
Ins Owner Change0%
Market Cap1.02B
Analysts86.67
Price Target38.76 (66.39%)
Short Float %4.96%
Short Ratio8.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.93%
Min EPS beat(2)-49.66%
Max EPS beat(2)11.81%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)14.84%
PT rev (3m)4.26%
EPS NQ rev (1m)14.73%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.16%
EPS NY rev (3m)-37.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE 291.19
Fwd PE N/A
P/S 6.1
P/FCF N/A
P/OCF N/A
P/B 3.9
P/tB 3.9
EV/EBITDA 13.62
EPS(TTM)0.08
EY0.34%
EPS(NY)-3.19
Fwd EYN/A
FCF(TTM)-2.43
FCFYN/A
OCF(TTM)-2.4
OCFYN/A
SpS3.82
BVpS5.98
TBVpS5.98
PEG (NY)3.45
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.12%
ROE 1.3%
ROCE 20.3%
ROIC 16.04%
ROICexc 238.46%
ROICexgc 238.46%
OM 34.38%
PM (TTM) 2.03%
GM N/A
FCFM N/A
ROA(3y)-71.89%
ROA(5y)N/A
ROE(3y)-370.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 49.54%
Cap/Sales 0.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.63
Quick Ratio 13.63
Altman-Z 16.02
F-Score6
WACC9.91%
ROIC/WACC1.62
Cap/Depr(3y)32.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)103.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-413.49%
EPS Next Y84.51%
EPS Next 2Y36.71%
EPS Next 3Y23.23%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-72.91%
Revenue Next 5YN/A
EBIT growth 1Y158.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-708.92%
EBIT Next 3Y-111.8%
EBIT Next 5YN/A
FCF growth 1Y185.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y187.48%
OCF growth 3YN/A
OCF growth 5YN/A